TNFRSF8 and Hodgkins lymphoma: The phase 2 NCT00848926 trial showed the efficacy of monotherapy BV for R/R CD30‐positive HL patients after an autologous stem‐cell transplantation (ASCT) or at least two lines of multiagent chemotherapies (ORR: 75%; CR rate: 34%; adverse event [AE] over grade 3: 55%; 5‐year progression‐free survival [PFS] rate: 22%; 5‐year OS rate: 41%).65, 66